Bio Pharma Dive
FEBRUARY 15, 2024
Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.
Pharmaceutical Technology
FEBRUARY 15, 2024
The success of recent trials treating mental health problems with psychedelic therapies has driven a rapid rise in investment in the area.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 15, 2024
Scientists have revealed in unprecedented detail how obesity affects mitochondria in mice, causing the cellular powerhouses to fragment into smaller pieces. Mitochondria are famous as “powerhouses of the cell,” given their crucial role in generating energy. Yet the vital work of these organelles is often impaired in people with obesity, for reasons that remain unclear.
Pharmaceutical Technology
FEBRUARY 15, 2024
As the market is progressively becoming saturated by GLP-1 receptor agonists, companies are investigating alternative mechanisms of action.
Bio Pharma Dive
FEBRUARY 15, 2024
The partnership will use Intellia's "DNA writing” technology, and initially focus on people with the lung disease who have limited or no available treatment options.
Pharmaceutical Technology
FEBRUARY 15, 2024
The US FDA has granted approval for Eicos Sciences' Aurlumyn for adults with severe frostbite to lower the risk of amputation.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 15, 2024
GSK has exercised its option for a licence for Elsie Biotechnologies’ discovery platform to detect and develop new oligonucleotides.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 15, 2024
Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, announced that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year. These accolades highlight Agilent’s commitment to innovation and excellence in drug discovery and development.
Pharmaceutical Technology
FEBRUARY 15, 2024
In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.
Bio Pharma Dive
FEBRUARY 15, 2024
The Canadian lupus drug developer said it engaged more than 60 parties during its eight-month business review, but only one expressed interest before walking away.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
FEBRUARY 15, 2024
Ono Pharmaceutical has entered an agreement with Numab Therapeutics for developing and commercialising NM49 in the oncology field.
BioPharma Reporter
FEBRUARY 15, 2024
PrecisionLife has partnered with healthcare center the Metrodora Institute to jumpstart the diagnosis and treatment options for a range of chronic diseases including long COVID, ME/CFS, ALS and SjÃgren's syndrome.
Pharmaceutical Technology
FEBRUARY 15, 2024
Latigo Biotherapeutics has secured $135m in a Series A funding round to advance the development of its non-opioid pain medicines.
XTalks
FEBRUARY 15, 2024
February is Black History Month, a time dedicated to celebrating the achievements and contributions of African Americans throughout history. In the life sciences, countless Black scientists, researchers and medical professionals have made groundbreaking discoveries that have significantly advanced our understanding of biology and medicine. Their outstanding achievements are even more remarkable given that many worked during dark times of racial discrimination and segregation.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
FEBRUARY 15, 2024
The HHS provides guidance on using online tracking technologies in a HIPAA-compliant manner. Learn how to ensure your analytics practices align with healthcare regulations and protect patient privacy.
XTalks
FEBRUARY 15, 2024
The Good Food Prescription program, designed to combat diet-related conditions, combines expert clinical coaching, personalized meal planning and medically tailored grocery deliveries in partnership with Instacart. In this episode of the Xtalks Food Podcast, Sydney talks about this program from Good Measures, a company founded with a vision to revolutionize the intersection of nutrition and health management.
Fierce Pharma
FEBRUARY 15, 2024
Even as Catalent moves toward a $16.5 billion sale to Novo Holdings, hundreds of the CDMO's former staffers won't be in the mix going forward. | A recent buyout announcement didn't spare Catalent staffers from layoffs after the company this week revealed it's trimmed hundreds of jobs over the last few months. The move forms part of an ongoing restructuring scheme at Catalent.
Drug Patent Watch
FEBRUARY 15, 2024
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable… The post Drug Excipient Business Development Reports now Available on Amazon appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
FEBRUARY 15, 2024
Changing a clinical trial’s statistical analysis plan on the cusp of a readout? | Changing a clinical trial’s statistical analysis plan on the cusp of a readout? That’s exactly what Alnylam just did for a closely watched study of its next-generation RNA interference therapy Amvuttra in a rare heart disease.
Outsourcing Pharma
FEBRUARY 15, 2024
Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
pharmaphorum
FEBRUARY 15, 2024
Healthtech specialist Innsena has committed funding and expertise to CancerX, launched last year to encourage the use of digital health technologies to overcome challenges in cancer care.
Pharmaceutical Commerce
FEBRUARY 15, 2024
Patients with severe frostbite who were administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
FEBRUARY 15, 2024
Exercise matched psychotherapy and was more effective than medication as a treatment for #depression in a meta-analysis of randomised clinical trials
Pharma Times
FEBRUARY 15, 2024
CLM-HT01 improved blood pressure and minimised adverse reactions in patients
pharmaphorum
FEBRUARY 15, 2024
Gene-editing biotech Prime Medicine has priced an initial public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge, Massachusetts-based company is offering 19.2 million shares at $6.25 each and expects to start trading on the Nasdaq on 20th February under the PRME symbol.
Pharma Times
FEBRUARY 15, 2024
In Europe, stroke-related brain-bleed deaths are expected to increase by 8.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Fierce Pharma
FEBRUARY 15, 2024
With a $93 million settlement, Pfizer can wash its hands of more than a decade's worth of antitrust litigation over the once-lucrative cholesterol med Lipitor. | Purchasers have long accused Pfizer—and Sun Pharma's Ranbaxy—of conspiring to keep Lipitor generics off the market with a "reverse payment" agreement. After the Pfizer settlement, the class action lawsuit against Ranbaxy will continue.
pharmaphorum
FEBRUARY 15, 2024
The FTC is investigating wholesalers and other middlemen in the pharma supply chain to assess their possible role in worsening shortages of generic medicines
Pharma Tutor
FEBRUARY 15, 2024
Anti-Stress Skin Care admin Thu, 02/15/2024 - 16:12 Vinay Kumar Singh. Head-Formulation Kumar Organic Products Research Centre Pvt. Ltd., Bengaluru Email : formulation_krc@kopresearchcentre.
Fierce Pharma
FEBRUARY 15, 2024
As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new sch | As Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new schizophrenia and bipolar disorder drug Lybalvi.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
311 
Let's personalize your content